Prof. Hanaa Banjar
King Faisal Specialist Hospital & Research Centre, KSATitle: Application of Cystic Fibrosis (CF) gene modifiers to the CF population to improve survival and quality of life in Saudi Arabia and the Gulf area
Abstract
Background: Cystic Fibrosis transmembrane regulator gene (CFTR gene modifiers) has been effective in 50-90% of the CF population in North America and Western Europe which showed marked improvement in the median survival and quality of life. Its application to the Arabian Gulf countries has not been studied due to the presence of different and Novel CFTR mutations.
Objective: To determine the applications of the (CF) gene modifiers to the CFTR variants in the CF population of the Arabian Gulf countries.
Results: Around 40% of the Saudi CFTR mutations will be benefit from the available Cf modifiers, 80% in Qatar, UAE in 50-70%, and in Oman in 60%. Of the CFTR mutations that will benefit from the gene modifiers in KSA according to the % affected CF population are: p.Ile1234Val (11%), F508del (11%), 711+1G>T (10%), p.His139Leu (6.4%), and p.Ser549Arg (4.5%), which constitute a total of 42%. In Qatar: p.Ile1234Val (66%), and F508del (15.6%), which constitute a total of 22%. In Oman: p.Ser549Arg (52%), and F508del (12.5%), which constitute a total of 64.5%. UAE: p.Ser549Arg (10%), and F508del (30%), and p.Ile1234Val (30%), which constitute a total of 70%.
Conclusion: CFTR modifiers will improve the median survival and the quality of life of the CF population in the Arabian Gulf area similar to the western countries.
Biography
Hanaa Banjar is a professor of pediatrics at Alfaisal University, Riyadh since 2013, She is also a consultant pediatric pulmonology and the director of pediatric pulmonology fellowship program at King Faisal Specialist Hospital and Research Center, Riyadh. She received her residency in pediatrics from the University of Ottawa, Ontario, Canada and her pulmonary fellowship from McGill University, Montreal, Quebec, Canada. As an expert in pediatric pulmonary medicine, especially in cystic fibrosis, pulmonary hypertension, and Non-CF Bronchiectasis, she serves as the principle investigator of the cystic Fibrosis registry of up to 400 patients and the principle author of 90 articles.
Organization Location
1309 Coffeen Avenue, STE 1200, Sheridan, Wyoming 82801, USA
Mail us at
Program Enquiry
palliativecare@scientexconferences.com
General Enquiry
contact@scientexconferences.com
Registration Enquiry
finance@scientexconferences.com
palliativecare@scientexevents.org
Our Social Presence
Call us at
USA :(+1) 914 520 5013